Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422582 | 0.89 | P2RX7 (0.43) | P2RX7HRH3L3MBTL1NPC1CYP3A4 | |
| SCHEMBL2416409 | 0.86 | ALDH1A1 (0.47) | HRH3L3MBTL1CYP3A4KMT2APOLB | |
| SCHEMBL2424265 | 0.85 | ADRA2C (0.45) | P2RX7HRH3CYP3A4TSHRKMT2A | |
| SCHEMBL2418919 | 0.84 | ALDH1A1 (0.54) | HRH3L3MBTL1NPC1CYP3A4KMT2A | |
| SCHEMBL2417348 | 0.84 | ADRA2C (0.46) | HRH3CYP3A4CYP2C19KMT2A | |
| SCHEMBL2417760 | 0.84 | NPC1 (0.48) | P2RX7HRH3L3MBTL1NPC1CYP3A4 | |
| SCHEMBL2422035 | 0.83 | KDM4E (0.43) | P2RX7HRH3L3MBTL1NPC1TSHR | |
| SCHEMBL2418907 | 0.82 | HTT (0.46) | KMT2A | |
| SCHEMBL30795036 | 0.80 | DRD1 (0.48) | P2RX7HRH3L3MBTL1NPC1TSHR | |
| SCHEMBL3243040 | 0.80 | DRD1 (0.48) | P2RX7HRH3L3MBTL1NPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2112993-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS HAVING AFFINITY WITH THE KCNQ2/3 K+ CHANNEL AND USE THEREOF IN MEDICAMENTS | Grünenthal GmbH (DE) | 2009-11-04 | — | — | EP | claimed |
| WO-2008046582-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS HAVING AFFINITY WITH THE KCNQ2/3 K+ CHANNEL AND USE THEREOF IN MEDICAMENTS | Grünenthal GmbH (DE) | 2008-04-24 | — | — | WO | claimed |
| US-8017772-B2 | Substituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-8017772-B2 | Substituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20100004252-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN | GRUENENTHAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004252-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN | GRUENENTHAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
| US-7625900-B2 | Sutstituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-7625900-B2 | Sutstituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-7625900-B2 | Sutstituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| EP-2112993-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS HAVING AFFINITY WITH THE KCNQ2/3 K+ CHANNEL AND USE THEREOF IN MEDICAMENTS | Grünenthal GmbH (DE) | 2009-11-04 | — | — | EP | disclosed |
| US-20080167315-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain | GRUENENTHAL GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167315-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain | GRUENENTHAL GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167315-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain | GRUENENTHAL GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008046582-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS HAVING AFFINITY WITH THE KCNQ2/3 K+ CHANNEL AND USE THEREOF IN MEDICAMENTS | Grünenthal GmbH (DE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008046582-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS HAVING AFFINITY WITH THE KCNQ2/3 K+ CHANNEL AND USE THEREOF IN MEDICAMENTS | Grünenthal GmbH (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004252-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN | KCNQ2, KCNQ1, KCNJ2 | P2RX7 149/4885HRH3 1137/4885L3MBTL1 3956/4885 |
| US-20080167315-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain | KCNQ2, KCNQ1, KCNJ2 | P2RX7 149/4885HRH3 1137/4885L3MBTL1 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.